Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan

[Business Wire] – FOSTER CITY, Calif.–(BUSINESSWIRE)– Gilead Sciences, Inc. (Nasdaq:GILD – News) today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor . . . → Read More: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan No similar articles.